nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—ABCG2—Dactinomycin—muscle cancer	0.197	0.274	CbGbCtD
Leflunomide—ABCG2—Vincristine—muscle cancer	0.121	0.169	CbGbCtD
Leflunomide—ABCG2—Etoposide—muscle cancer	0.111	0.155	CbGbCtD
Leflunomide—CYP1A2—Dacarbazine—muscle cancer	0.0937	0.13	CbGbCtD
Leflunomide—ABCG2—Doxorubicin—muscle cancer	0.0758	0.106	CbGbCtD
Leflunomide—ABCG2—Methotrexate—muscle cancer	0.0735	0.102	CbGbCtD
Leflunomide—CYP1A2—Etoposide—muscle cancer	0.0458	0.0638	CbGbCtD
Leflunomide—DHODH—cardiac atrium—muscle cancer	0.00548	0.085	CbGeAlD
Leflunomide—PTK2B—embryo—muscle cancer	0.00512	0.0795	CbGeAlD
Leflunomide—DHODH—tendon—muscle cancer	0.00477	0.0741	CbGeAlD
Leflunomide—DHODH—head—muscle cancer	0.00409	0.0635	CbGeAlD
Leflunomide—PTK2B—smooth muscle tissue—muscle cancer	0.00402	0.0625	CbGeAlD
Leflunomide—DHODH—testis—muscle cancer	0.00395	0.0614	CbGeAlD
Leflunomide—PTK2B—renal system—muscle cancer	0.00387	0.0602	CbGeAlD
Leflunomide—Niflumic Acid—PTGS2—muscle cancer	0.00356	1	CrCbGaD
Leflunomide—AHR—smooth muscle tissue—muscle cancer	0.00331	0.0514	CbGeAlD
Leflunomide—PTK2B—tendon—muscle cancer	0.00302	0.047	CbGeAlD
Leflunomide—PTK2B—bone marrow—muscle cancer	0.00293	0.0455	CbGeAlD
Leflunomide—AHR—cardiac atrium—muscle cancer	0.00285	0.0443	CbGeAlD
Leflunomide—PTK2B—vagina—muscle cancer	0.00281	0.0436	CbGeAlD
Leflunomide—PTK2B—head—muscle cancer	0.00259	0.0403	CbGeAlD
Leflunomide—PTK2B—testis—muscle cancer	0.0025	0.0389	CbGeAlD
Leflunomide—AHR—tendon—muscle cancer	0.00249	0.0386	CbGeAlD
Leflunomide—AHR—bone marrow—muscle cancer	0.00241	0.0374	CbGeAlD
Leflunomide—AHR—vagina—muscle cancer	0.00231	0.0358	CbGeAlD
Leflunomide—AHR—testis—muscle cancer	0.00206	0.032	CbGeAlD
Leflunomide—CYP1A2—renal system—muscle cancer	0.00119	0.0185	CbGeAlD
Leflunomide—ABCG2—bone marrow—muscle cancer	0.000934	0.0145	CbGeAlD
Leflunomide—ABCG2—vagina—muscle cancer	0.000895	0.0139	CbGeAlD
Leflunomide—ABCG2—testis—muscle cancer	0.000798	0.0124	CbGeAlD
Leflunomide—Leukopenia—Etoposide—muscle cancer	0.000381	0.00178	CcSEcCtD
Leflunomide—Abdominal pain—Dactinomycin—muscle cancer	0.00038	0.00178	CcSEcCtD
Leflunomide—Body temperature increased—Dactinomycin—muscle cancer	0.00038	0.00178	CcSEcCtD
Leflunomide—Anaphylactoid reaction—Doxorubicin—muscle cancer	0.000379	0.00177	CcSEcCtD
Leflunomide—Decreased appetite—Vincristine—muscle cancer	0.000373	0.00175	CcSEcCtD
Leflunomide—Cough—Etoposide—muscle cancer	0.000372	0.00174	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Vincristine—muscle cancer	0.00037	0.00173	CcSEcCtD
Leflunomide—Fatigue—Vincristine—muscle cancer	0.00037	0.00173	CcSEcCtD
Leflunomide—Hypertension—Etoposide—muscle cancer	0.000368	0.00172	CcSEcCtD
Leflunomide—Constipation—Vincristine—muscle cancer	0.000367	0.00172	CcSEcCtD
Leflunomide—Pain—Vincristine—muscle cancer	0.000367	0.00172	CcSEcCtD
Leflunomide—Osteoarthritis—Doxorubicin—muscle cancer	0.000367	0.00172	CcSEcCtD
Leflunomide—Asthma—Methotrexate—muscle cancer	0.000366	0.00171	CcSEcCtD
Leflunomide—Chest pain—Etoposide—muscle cancer	0.000363	0.0017	CcSEcCtD
Leflunomide—Eosinophilia—Methotrexate—muscle cancer	0.000362	0.0017	CcSEcCtD
Leflunomide—Migraine—Doxorubicin—muscle cancer	0.000361	0.00169	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00036	0.00169	CcSEcCtD
Leflunomide—Pancreatitis—Methotrexate—muscle cancer	0.000359	0.00168	CcSEcCtD
Leflunomide—Discomfort—Etoposide—muscle cancer	0.000358	0.00168	CcSEcCtD
Leflunomide—Hypersensitivity—Dactinomycin—muscle cancer	0.000354	0.00166	CcSEcCtD
Leflunomide—Gastrointestinal pain—Vincristine—muscle cancer	0.000351	0.00164	CcSEcCtD
Leflunomide—Pancytopenia—Methotrexate—muscle cancer	0.000348	0.00163	CcSEcCtD
Leflunomide—Anaphylactic shock—Etoposide—muscle cancer	0.000348	0.00163	CcSEcCtD
Leflunomide—Infection—Etoposide—muscle cancer	0.000345	0.00162	CcSEcCtD
Leflunomide—Asthenia—Dactinomycin—muscle cancer	0.000345	0.00161	CcSEcCtD
Leflunomide—Dysuria—Methotrexate—muscle cancer	0.000342	0.0016	CcSEcCtD
Leflunomide—Neutropenia—Methotrexate—muscle cancer	0.000342	0.0016	CcSEcCtD
Leflunomide—Thrombocytopenia—Etoposide—muscle cancer	0.00034	0.00159	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Methotrexate—muscle cancer	0.00034	0.00159	CcSEcCtD
Leflunomide—Tachycardia—Etoposide—muscle cancer	0.000339	0.00159	CcSEcCtD
Leflunomide—Abdominal pain—Vincristine—muscle cancer	0.000339	0.00159	CcSEcCtD
Leflunomide—Body temperature increased—Vincristine—muscle cancer	0.000339	0.00159	CcSEcCtD
Leflunomide—Liver function test abnormal—Doxorubicin—muscle cancer	0.000339	0.00158	CcSEcCtD
Leflunomide—Skin disorder—Etoposide—muscle cancer	0.000338	0.00158	CcSEcCtD
Leflunomide—Dry skin—Doxorubicin—muscle cancer	0.000336	0.00157	CcSEcCtD
Leflunomide—Hyperhidrosis—Etoposide—muscle cancer	0.000336	0.00157	CcSEcCtD
Leflunomide—Hypokalaemia—Doxorubicin—muscle cancer	0.000334	0.00156	CcSEcCtD
Leflunomide—Breast disorder—Doxorubicin—muscle cancer	0.000331	0.00155	CcSEcCtD
Leflunomide—Anorexia—Etoposide—muscle cancer	0.000331	0.00155	CcSEcCtD
Leflunomide—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.00033	0.00155	CcSEcCtD
Leflunomide—Diarrhoea—Dactinomycin—muscle cancer	0.000329	0.00154	CcSEcCtD
Leflunomide—Pneumonia—Methotrexate—muscle cancer	0.000328	0.00154	CcSEcCtD
Leflunomide—Infestation NOS—Methotrexate—muscle cancer	0.000326	0.00153	CcSEcCtD
Leflunomide—Infestation—Methotrexate—muscle cancer	0.000326	0.00153	CcSEcCtD
Leflunomide—Hypotension—Etoposide—muscle cancer	0.000325	0.00152	CcSEcCtD
Leflunomide—Gastritis—Doxorubicin—muscle cancer	0.000325	0.00152	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000324	0.00151	CcSEcCtD
Leflunomide—Renal failure—Methotrexate—muscle cancer	0.000321	0.0015	CcSEcCtD
Leflunomide—Stomatitis—Methotrexate—muscle cancer	0.000318	0.00149	CcSEcCtD
Leflunomide—Conjunctivitis—Methotrexate—muscle cancer	0.000317	0.00148	CcSEcCtD
Leflunomide—Influenza—Doxorubicin—muscle cancer	0.000317	0.00148	CcSEcCtD
Leflunomide—Asthma—Doxorubicin—muscle cancer	0.000317	0.00148	CcSEcCtD
Leflunomide—Hypersensitivity—Vincristine—muscle cancer	0.000316	0.00148	CcSEcCtD
Leflunomide—Eosinophilia—Doxorubicin—muscle cancer	0.000314	0.00147	CcSEcCtD
Leflunomide—Paraesthesia—Etoposide—muscle cancer	0.000312	0.00146	CcSEcCtD
Leflunomide—Haematuria—Methotrexate—muscle cancer	0.000311	0.00146	CcSEcCtD
Leflunomide—Pancreatitis—Doxorubicin—muscle cancer	0.000311	0.00145	CcSEcCtD
Leflunomide—Dyspnoea—Etoposide—muscle cancer	0.00031	0.00145	CcSEcCtD
Leflunomide—Angina pectoris—Doxorubicin—muscle cancer	0.000309	0.00145	CcSEcCtD
Leflunomide—Hepatobiliary disease—Methotrexate—muscle cancer	0.000309	0.00144	CcSEcCtD
Leflunomide—Epistaxis—Methotrexate—muscle cancer	0.000308	0.00144	CcSEcCtD
Leflunomide—Asthenia—Vincristine—muscle cancer	0.000308	0.00144	CcSEcCtD
Leflunomide—Vomiting—Dactinomycin—muscle cancer	0.000305	0.00143	CcSEcCtD
Leflunomide—Bronchitis—Doxorubicin—muscle cancer	0.000305	0.00143	CcSEcCtD
Leflunomide—Agranulocytosis—Methotrexate—muscle cancer	0.000305	0.00143	CcSEcCtD
Leflunomide—Rash—Dactinomycin—muscle cancer	0.000303	0.00142	CcSEcCtD
Leflunomide—Decreased appetite—Etoposide—muscle cancer	0.000302	0.00141	CcSEcCtD
Leflunomide—Pancytopenia—Doxorubicin—muscle cancer	0.000301	0.00141	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Etoposide—muscle cancer	0.0003	0.0014	CcSEcCtD
Leflunomide—Fatigue—Etoposide—muscle cancer	0.0003	0.0014	CcSEcCtD
Leflunomide—Pain—Etoposide—muscle cancer	0.000297	0.00139	CcSEcCtD
Leflunomide—Constipation—Etoposide—muscle cancer	0.000297	0.00139	CcSEcCtD
Leflunomide—Dysuria—Doxorubicin—muscle cancer	0.000296	0.00139	CcSEcCtD
Leflunomide—Neutropenia—Doxorubicin—muscle cancer	0.000296	0.00139	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.000295	0.00138	CcSEcCtD
Leflunomide—Haemoglobin—Methotrexate—muscle cancer	0.000294	0.00138	CcSEcCtD
Leflunomide—Diarrhoea—Vincristine—muscle cancer	0.000294	0.00137	CcSEcCtD
Leflunomide—Haemorrhage—Methotrexate—muscle cancer	0.000293	0.00137	CcSEcCtD
Leflunomide—Hepatitis—Methotrexate—muscle cancer	0.000293	0.00137	CcSEcCtD
Leflunomide—Pollakiuria—Doxorubicin—muscle cancer	0.000293	0.00137	CcSEcCtD
Leflunomide—Pharyngitis—Methotrexate—muscle cancer	0.000291	0.00136	CcSEcCtD
Leflunomide—Urinary tract disorder—Methotrexate—muscle cancer	0.000289	0.00135	CcSEcCtD
Leflunomide—Urethral disorder—Methotrexate—muscle cancer	0.000287	0.00134	CcSEcCtD
Leflunomide—Weight decreased—Doxorubicin—muscle cancer	0.000287	0.00134	CcSEcCtD
Leflunomide—Feeling abnormal—Etoposide—muscle cancer	0.000286	0.00134	CcSEcCtD
Leflunomide—Hyperglycaemia—Doxorubicin—muscle cancer	0.000286	0.00134	CcSEcCtD
Leflunomide—Nausea—Dactinomycin—muscle cancer	0.000285	0.00133	CcSEcCtD
Leflunomide—Pneumonia—Doxorubicin—muscle cancer	0.000284	0.00133	CcSEcCtD
Leflunomide—Gastrointestinal pain—Etoposide—muscle cancer	0.000284	0.00133	CcSEcCtD
Leflunomide—Dizziness—Vincristine—muscle cancer	0.000284	0.00133	CcSEcCtD
Leflunomide—Infestation—Doxorubicin—muscle cancer	0.000283	0.00132	CcSEcCtD
Leflunomide—Infestation NOS—Doxorubicin—muscle cancer	0.000283	0.00132	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.00028	0.00131	CcSEcCtD
Leflunomide—Renal failure—Doxorubicin—muscle cancer	0.000278	0.0013	CcSEcCtD
Leflunomide—Erythema multiforme—Methotrexate—muscle cancer	0.000277	0.0013	CcSEcCtD
Leflunomide—Neuropathy peripheral—Doxorubicin—muscle cancer	0.000277	0.0013	CcSEcCtD
Leflunomide—Urticaria—Etoposide—muscle cancer	0.000276	0.00129	CcSEcCtD
Leflunomide—Jaundice—Doxorubicin—muscle cancer	0.000275	0.00129	CcSEcCtD
Leflunomide—Stomatitis—Doxorubicin—muscle cancer	0.000275	0.00129	CcSEcCtD
Leflunomide—Abdominal pain—Etoposide—muscle cancer	0.000275	0.00129	CcSEcCtD
Leflunomide—Body temperature increased—Etoposide—muscle cancer	0.000275	0.00129	CcSEcCtD
Leflunomide—Conjunctivitis—Doxorubicin—muscle cancer	0.000275	0.00129	CcSEcCtD
Leflunomide—Urinary tract infection—Doxorubicin—muscle cancer	0.000275	0.00129	CcSEcCtD
Leflunomide—Eye disorder—Methotrexate—muscle cancer	0.000274	0.00128	CcSEcCtD
Leflunomide—Vomiting—Vincristine—muscle cancer	0.000273	0.00128	CcSEcCtD
Leflunomide—Cardiac disorder—Methotrexate—muscle cancer	0.000272	0.00127	CcSEcCtD
Leflunomide—Rash—Vincristine—muscle cancer	0.00027	0.00127	CcSEcCtD
Leflunomide—Dermatitis—Vincristine—muscle cancer	0.00027	0.00126	CcSEcCtD
Leflunomide—Haematuria—Doxorubicin—muscle cancer	0.000269	0.00126	CcSEcCtD
Leflunomide—Headache—Vincristine—muscle cancer	0.000269	0.00126	CcSEcCtD
Leflunomide—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000267	0.00125	CcSEcCtD
Leflunomide—Epistaxis—Doxorubicin—muscle cancer	0.000267	0.00125	CcSEcCtD
Leflunomide—Sinusitis—Doxorubicin—muscle cancer	0.000265	0.00124	CcSEcCtD
Leflunomide—Immune system disorder—Methotrexate—muscle cancer	0.000265	0.00124	CcSEcCtD
Leflunomide—Mediastinal disorder—Methotrexate—muscle cancer	0.000264	0.00124	CcSEcCtD
Leflunomide—Agranulocytosis—Doxorubicin—muscle cancer	0.000264	0.00123	CcSEcCtD
Leflunomide—Chills—Methotrexate—muscle cancer	0.000263	0.00123	CcSEcCtD
Leflunomide—Alopecia—Methotrexate—muscle cancer	0.000259	0.00121	CcSEcCtD
Leflunomide—Mental disorder—Methotrexate—muscle cancer	0.000257	0.0012	CcSEcCtD
Leflunomide—Hypersensitivity—Etoposide—muscle cancer	0.000256	0.0012	CcSEcCtD
Leflunomide—Malnutrition—Methotrexate—muscle cancer	0.000255	0.00119	CcSEcCtD
Leflunomide—Haemoglobin—Doxorubicin—muscle cancer	0.000255	0.00119	CcSEcCtD
Leflunomide—Nausea—Vincristine—muscle cancer	0.000255	0.00119	CcSEcCtD
Leflunomide—Rhinitis—Doxorubicin—muscle cancer	0.000254	0.00119	CcSEcCtD
Leflunomide—Hepatitis—Doxorubicin—muscle cancer	0.000254	0.00119	CcSEcCtD
Leflunomide—Haemorrhage—Doxorubicin—muscle cancer	0.000254	0.00119	CcSEcCtD
Leflunomide—Pharyngitis—Doxorubicin—muscle cancer	0.000252	0.00118	CcSEcCtD
Leflunomide—Urinary tract disorder—Doxorubicin—muscle cancer	0.000251	0.00117	CcSEcCtD
Leflunomide—Oedema peripheral—Doxorubicin—muscle cancer	0.00025	0.00117	CcSEcCtD
Leflunomide—Dysgeusia—Methotrexate—muscle cancer	0.00025	0.00117	CcSEcCtD
Leflunomide—Asthenia—Etoposide—muscle cancer	0.000249	0.00117	CcSEcCtD
Leflunomide—Connective tissue disorder—Doxorubicin—muscle cancer	0.000249	0.00117	CcSEcCtD
Leflunomide—Urethral disorder—Doxorubicin—muscle cancer	0.000249	0.00116	CcSEcCtD
Leflunomide—Back pain—Methotrexate—muscle cancer	0.000247	0.00115	CcSEcCtD
Leflunomide—Pruritus—Etoposide—muscle cancer	0.000246	0.00115	CcSEcCtD
Leflunomide—Vision blurred—Methotrexate—muscle cancer	0.00024	0.00113	CcSEcCtD
Leflunomide—Erythema multiforme—Doxorubicin—muscle cancer	0.00024	0.00112	CcSEcCtD
Leflunomide—Diarrhoea—Etoposide—muscle cancer	0.000238	0.00111	CcSEcCtD
Leflunomide—Eye disorder—Doxorubicin—muscle cancer	0.000237	0.00111	CcSEcCtD
Leflunomide—Ill-defined disorder—Methotrexate—muscle cancer	0.000237	0.00111	CcSEcCtD
Leflunomide—Anaemia—Methotrexate—muscle cancer	0.000236	0.0011	CcSEcCtD
Leflunomide—Cardiac disorder—Doxorubicin—muscle cancer	0.000235	0.0011	CcSEcCtD
Leflunomide—Malaise—Methotrexate—muscle cancer	0.00023	0.00108	CcSEcCtD
Leflunomide—Dizziness—Etoposide—muscle cancer	0.00023	0.00108	CcSEcCtD
Leflunomide—Immune system disorder—Doxorubicin—muscle cancer	0.000229	0.00107	CcSEcCtD
Leflunomide—Vertigo—Methotrexate—muscle cancer	0.000229	0.00107	CcSEcCtD
Leflunomide—Mediastinal disorder—Doxorubicin—muscle cancer	0.000229	0.00107	CcSEcCtD
Leflunomide—Leukopenia—Methotrexate—muscle cancer	0.000228	0.00107	CcSEcCtD
Leflunomide—Chills—Doxorubicin—muscle cancer	0.000228	0.00107	CcSEcCtD
Leflunomide—Arrhythmia—Doxorubicin—muscle cancer	0.000227	0.00106	CcSEcCtD
Leflunomide—Alopecia—Doxorubicin—muscle cancer	0.000224	0.00105	CcSEcCtD
Leflunomide—Cough—Methotrexate—muscle cancer	0.000223	0.00104	CcSEcCtD
Leflunomide—Mental disorder—Doxorubicin—muscle cancer	0.000222	0.00104	CcSEcCtD
Leflunomide—Vomiting—Etoposide—muscle cancer	0.000221	0.00103	CcSEcCtD
Leflunomide—Malnutrition—Doxorubicin—muscle cancer	0.000221	0.00103	CcSEcCtD
Leflunomide—Rash—Etoposide—muscle cancer	0.000219	0.00103	CcSEcCtD
Leflunomide—Dermatitis—Etoposide—muscle cancer	0.000219	0.00102	CcSEcCtD
Leflunomide—Headache—Etoposide—muscle cancer	0.000218	0.00102	CcSEcCtD
Leflunomide—Flatulence—Doxorubicin—muscle cancer	0.000218	0.00102	CcSEcCtD
Leflunomide—Chest pain—Methotrexate—muscle cancer	0.000217	0.00102	CcSEcCtD
Leflunomide—Arthralgia—Methotrexate—muscle cancer	0.000217	0.00102	CcSEcCtD
Leflunomide—Myalgia—Methotrexate—muscle cancer	0.000217	0.00102	CcSEcCtD
Leflunomide—Dysgeusia—Doxorubicin—muscle cancer	0.000216	0.00101	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000216	0.00101	CcSEcCtD
Leflunomide—Discomfort—Methotrexate—muscle cancer	0.000215	0.001	CcSEcCtD
Leflunomide—Back pain—Doxorubicin—muscle cancer	0.000214	0.001	CcSEcCtD
Leflunomide—Muscle spasms—Doxorubicin—muscle cancer	0.000212	0.000994	CcSEcCtD
Leflunomide—Anaphylactic shock—Methotrexate—muscle cancer	0.000208	0.000974	CcSEcCtD
Leflunomide—Vision blurred—Doxorubicin—muscle cancer	0.000208	0.000974	CcSEcCtD
Leflunomide—Infection—Methotrexate—muscle cancer	0.000207	0.000968	CcSEcCtD
Leflunomide—Nausea—Etoposide—muscle cancer	0.000206	0.000966	CcSEcCtD
Leflunomide—Ill-defined disorder—Doxorubicin—muscle cancer	0.000205	0.000959	CcSEcCtD
Leflunomide—Nervous system disorder—Methotrexate—muscle cancer	0.000204	0.000955	CcSEcCtD
Leflunomide—Anaemia—Doxorubicin—muscle cancer	0.000204	0.000955	CcSEcCtD
Leflunomide—Thrombocytopenia—Methotrexate—muscle cancer	0.000204	0.000954	CcSEcCtD
Leflunomide—Skin disorder—Methotrexate—muscle cancer	0.000202	0.000946	CcSEcCtD
Leflunomide—Hyperhidrosis—Methotrexate—muscle cancer	0.000201	0.000942	CcSEcCtD
Leflunomide—Malaise—Doxorubicin—muscle cancer	0.000199	0.000932	CcSEcCtD
Leflunomide—Vertigo—Doxorubicin—muscle cancer	0.000198	0.000929	CcSEcCtD
Leflunomide—Anorexia—Methotrexate—muscle cancer	0.000198	0.000929	CcSEcCtD
Leflunomide—Leukopenia—Doxorubicin—muscle cancer	0.000198	0.000925	CcSEcCtD
Leflunomide—Palpitations—Doxorubicin—muscle cancer	0.000195	0.000913	CcSEcCtD
Leflunomide—Hypotension—Methotrexate—muscle cancer	0.000195	0.00091	CcSEcCtD
Leflunomide—Cough—Doxorubicin—muscle cancer	0.000193	0.000902	CcSEcCtD
Leflunomide—Hypertension—Doxorubicin—muscle cancer	0.000191	0.000892	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.00019	0.000888	CcSEcCtD
Leflunomide—Insomnia—Methotrexate—muscle cancer	0.000188	0.000881	CcSEcCtD
Leflunomide—Arthralgia—Doxorubicin—muscle cancer	0.000188	0.00088	CcSEcCtD
Leflunomide—Chest pain—Doxorubicin—muscle cancer	0.000188	0.00088	CcSEcCtD
Leflunomide—Myalgia—Doxorubicin—muscle cancer	0.000188	0.00088	CcSEcCtD
Leflunomide—Anxiety—Doxorubicin—muscle cancer	0.000187	0.000877	CcSEcCtD
Leflunomide—Paraesthesia—Methotrexate—muscle cancer	0.000187	0.000875	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000187	0.000874	CcSEcCtD
Leflunomide—Discomfort—Doxorubicin—muscle cancer	0.000186	0.000869	CcSEcCtD
Leflunomide—Dyspnoea—Methotrexate—muscle cancer	0.000186	0.000869	CcSEcCtD
Leflunomide—Dry mouth—Doxorubicin—muscle cancer	0.000184	0.000861	CcSEcCtD
Leflunomide—Dyspepsia—Methotrexate—muscle cancer	0.000183	0.000858	CcSEcCtD
Leflunomide—Decreased appetite—Methotrexate—muscle cancer	0.000181	0.000847	CcSEcCtD
Leflunomide—Anaphylactic shock—Doxorubicin—muscle cancer	0.00018	0.000844	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00018	0.000841	CcSEcCtD
Leflunomide—Fatigue—Methotrexate—muscle cancer	0.000179	0.00084	CcSEcCtD
Leflunomide—Infection—Doxorubicin—muscle cancer	0.000179	0.000838	CcSEcCtD
Leflunomide—Pain—Methotrexate—muscle cancer	0.000178	0.000833	CcSEcCtD
Leflunomide—Nervous system disorder—Doxorubicin—muscle cancer	0.000177	0.000827	CcSEcCtD
Leflunomide—Thrombocytopenia—Doxorubicin—muscle cancer	0.000176	0.000826	CcSEcCtD
Leflunomide—Tachycardia—Doxorubicin—muscle cancer	0.000176	0.000823	CcSEcCtD
Leflunomide—Skin disorder—Doxorubicin—muscle cancer	0.000175	0.000819	CcSEcCtD
Leflunomide—Hyperhidrosis—Doxorubicin—muscle cancer	0.000174	0.000816	CcSEcCtD
Leflunomide—Anorexia—Doxorubicin—muscle cancer	0.000172	0.000804	CcSEcCtD
Leflunomide—Feeling abnormal—Methotrexate—muscle cancer	0.000172	0.000803	CcSEcCtD
Leflunomide—Gastrointestinal pain—Methotrexate—muscle cancer	0.00017	0.000797	CcSEcCtD
Leflunomide—Hypotension—Doxorubicin—muscle cancer	0.000168	0.000788	CcSEcCtD
Leflunomide—Urticaria—Methotrexate—muscle cancer	0.000165	0.000774	CcSEcCtD
Leflunomide—Abdominal pain—Methotrexate—muscle cancer	0.000165	0.00077	CcSEcCtD
Leflunomide—Body temperature increased—Methotrexate—muscle cancer	0.000165	0.00077	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000164	0.000769	CcSEcCtD
Leflunomide—Insomnia—Doxorubicin—muscle cancer	0.000163	0.000763	CcSEcCtD
Leflunomide—Paraesthesia—Doxorubicin—muscle cancer	0.000162	0.000758	CcSEcCtD
Leflunomide—Dyspnoea—Doxorubicin—muscle cancer	0.000161	0.000752	CcSEcCtD
Leflunomide—Dyspepsia—Doxorubicin—muscle cancer	0.000159	0.000743	CcSEcCtD
Leflunomide—Decreased appetite—Doxorubicin—muscle cancer	0.000157	0.000733	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000156	0.000728	CcSEcCtD
Leflunomide—Fatigue—Doxorubicin—muscle cancer	0.000155	0.000727	CcSEcCtD
Leflunomide—Constipation—Doxorubicin—muscle cancer	0.000154	0.000721	CcSEcCtD
Leflunomide—Pain—Doxorubicin—muscle cancer	0.000154	0.000721	CcSEcCtD
Leflunomide—Hypersensitivity—Methotrexate—muscle cancer	0.000153	0.000718	CcSEcCtD
Leflunomide—Asthenia—Methotrexate—muscle cancer	0.000149	0.000699	CcSEcCtD
Leflunomide—Feeling abnormal—Doxorubicin—muscle cancer	0.000149	0.000695	CcSEcCtD
Leflunomide—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000147	0.00069	CcSEcCtD
Leflunomide—Pruritus—Methotrexate—muscle cancer	0.000147	0.000689	CcSEcCtD
Leflunomide—Urticaria—Doxorubicin—muscle cancer	0.000143	0.00067	CcSEcCtD
Leflunomide—Abdominal pain—Doxorubicin—muscle cancer	0.000142	0.000667	CcSEcCtD
Leflunomide—Body temperature increased—Doxorubicin—muscle cancer	0.000142	0.000667	CcSEcCtD
Leflunomide—Diarrhoea—Methotrexate—muscle cancer	0.000142	0.000667	CcSEcCtD
Leflunomide—Dizziness—Methotrexate—muscle cancer	0.000138	0.000644	CcSEcCtD
Leflunomide—Hypersensitivity—Doxorubicin—muscle cancer	0.000133	0.000622	CcSEcCtD
Leflunomide—Vomiting—Methotrexate—muscle cancer	0.000132	0.000619	CcSEcCtD
Leflunomide—Rash—Methotrexate—muscle cancer	0.000131	0.000614	CcSEcCtD
Leflunomide—Dermatitis—Methotrexate—muscle cancer	0.000131	0.000614	CcSEcCtD
Leflunomide—Headache—Methotrexate—muscle cancer	0.00013	0.00061	CcSEcCtD
Leflunomide—Asthenia—Doxorubicin—muscle cancer	0.000129	0.000605	CcSEcCtD
Leflunomide—Pruritus—Doxorubicin—muscle cancer	0.000128	0.000597	CcSEcCtD
Leflunomide—Nausea—Methotrexate—muscle cancer	0.000124	0.000579	CcSEcCtD
Leflunomide—Diarrhoea—Doxorubicin—muscle cancer	0.000123	0.000577	CcSEcCtD
Leflunomide—Dizziness—Doxorubicin—muscle cancer	0.000119	0.000558	CcSEcCtD
Leflunomide—Vomiting—Doxorubicin—muscle cancer	0.000115	0.000536	CcSEcCtD
Leflunomide—Rash—Doxorubicin—muscle cancer	0.000114	0.000532	CcSEcCtD
Leflunomide—Dermatitis—Doxorubicin—muscle cancer	0.000114	0.000531	CcSEcCtD
Leflunomide—Headache—Doxorubicin—muscle cancer	0.000113	0.000529	CcSEcCtD
Leflunomide—Nausea—Doxorubicin—muscle cancer	0.000107	0.000501	CcSEcCtD
